Low molecular weight heparins reduce venous thromboembolism in cancer patients and may improve survival by directly affecting tumor biology.
Does antithrombotic therapy reduce the risk of venous thromboembolism in patients with cancer?
This editorial highlights the strong bidirectional association between cancer and venous thromboembolism, raising the question of whether antithrombotic therapy can mitigate this risk.
Two recent studies from Scandinavia 1 2 have reinforced the clear association between thrombosis and malignant disease that was first recognised by Trousseau in the 19th century.3 These population based analyses of cancer risk involved about 86 000 patients with venous thromboembolism, 4200 of whom had cancer. The observed incidence of cancer (especially pancreatic and ovarian) was 1.3 times the expected incidence among the Danish patients with either deep vein thrombosis or pulmonary embolus and 3.2 times the incidence among the Swedish patients. As a corollary, patients with established cancer are at increased risk of venous thromboembolism, which is potentially fatal. Patients with cancer are nearly twice as likely to die of pulmonary embolism in hospital as those with benign disease, and about 60% of these deaths occur prematurely.4 The hypercoagulable state of malignancy reflects tumour elaboration of tissue factor, the physiological procoagulant.5 Might antithrombotic treatment help reduce this high risk in patients with cancer? The risk of thrombosis is further increased when patients receive therapeutic interventions for their cancer. …
Kakkar et al. (Sat,) conducted a editorial in Cancer and venous thromboembolism. Low molecular weight heparins was evaluated. Low molecular weight heparins reduce venous thromboembolism in cancer patients and may improve survival by directly affecting tumor biology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: